### SUPERIOR MEDIASTINAL MASS LESION WITH SVC OBSTRUCTION

#### **Presenter:**

Dr. V. Karthik

2nd year PG

Dept of Pulmonology

#### **Moderator:**

Dr. R. Ramakrishna

**Professor & HOD** 

Dept of Pulmonology

### **CHIEF COMPLAINTS:**

 A 54 year old male patient, resident of Nekunampeta, who is a farmer by occupation, came to Respiratory medicine OPD with

• C/o hoarseness of voice since 1 month..

• C/o cough with expectoration since 10 days.

C/o shortness of breath since 1 week.

### **HISTORY OF PRESENT ILLNESS:**

• Patient was apparently well 1 month back.

Patient complaints started as

C/o hoarseness of voice since 1 month.

Loss of weight since 1 month.

Loss of appetite since 1 month.

 C/o cough with expectoration since 10 days which is whitish, scanty, mucoid.

- Aggravated during night time and during supine position and relieved on sitting.
- C/o shortness of breath grade III (acc. to mMRC grading) since 1 week which is insidious in onset, gradually progressing.

 Not associated with orthopnea or PND or swelling of feet or palpitations or abdominal distension. C/o facial swelling since 1 week

No C/o headache or blurring of vision.

No c/o fever or chest pain

No c/o wheeze or hemoptysis.

### PAST HISTORY:

No h/o PTB or BA or COVID.

No h/o CAD or CKD or CVA or Hypothyroidism.

 No h/o inhaler usage or seasonal variations or allergies.

No h/o HTN or DM.

#### **FAMILY HISTORY:**

No significant family history

### **PERSONAL HISTORY:**

Takes mixed diet.

Smoker for 35 years and stopped 1 month back.

 Known alcoholic for 35 years and stopped 1 month back.

No h/o biomass exposure or occupational exposure.

Normal bowel and bladder habits.

### **GENERAL EXAMINATION:**

Patient is moderatly built and ill nourished.

No signs of pallor, icterus, clubbing, pedal edema.

No signs of cyanosis.

No palpable lymphadenopathy.

 Engorged veins are seen on the left side of the neck.



#### **VITALS:**

• Temperature : Afebrile.

• Pulse rate: 90 bpm.

• **BP**: 120/80 mmHg.

• Respiratory rate: 22 cycles/min

• **SpO2**: 94% on RA.

### **INVESTIGATIONS:**

• CBP : Hb - 11.7 gm/dL

RBC - 4.05 million/cumm

WBC - 7000 cells/cumm

Platelets - 1.9 lakhs/cumm

Differential count:

N:51%

L:38%

E: 03%

M: 08%

• LFT within normal limits.

• RFT within normal limits.

• VIRALS: Non reactive.


• ECG: Normal.

• 2D ECHO: Normal.

### **RADIOLOGICAL FINDINGS:**

**CXR PA view** 







#### **✓ CECT CHEST findings:**

 Heterogeneously enhancing soft tissue density lesion in superior mediastinum with tumour invasion into SVC, other extensions and vascular relations - likely malignant etiology.

 Mediastinal and bilateral lower cervical lymphadeopathy.

Right adrenal and bone metastases.

 Left IJV thrombosis causing near total luminal narrowing. The patient was advised CT guided biopsy.

• CT guided biopsy was done on 16/7/2025 and sent for histopathological examination.

# SUPERIOR VENACAVA OBSTRUCTION SYNDROME

 Superior Vena Cava (SVC) obstruction refers to partial or complete blockage of blood flow through the SVC.


This is the major vein that returns blood from the head, neck, upper limbs, and upper thorax to the right atrium.

#### **ANATOMY OF SVC:**

 Formed by union of right and left brachiocephalic veins.

•Lies in the superior mediastinum, anterior to the trachea and right main bronchus.

#### Major veins superior to the heart



### **ETIOLOGY:**

Malignant Causes (80–85%).

✓ Bronchogenic carcinoma (NSCLC) – most common (~60% of SVCS).

✓ Lymphoma (especially non-Hodgkin's).


✓ Metastatic cancers (breast, testicular, thymoma, mediastinal tumors).

#### Benign Causes (15–20%)


- ✓ Thrombosis from indwelling catheters or pacemaker leads.
- ✓ Fibrosing mediastinitis (e.g., due to histoplasmosis or TB).
- ✓ Aortic aneurysm.
- ✓ Post-radiation fibrosis.

### PATHOPHYSIOLOGY:

- Obstruction leads to elevated venous pressure in areas drained by the SVC.
- Collateral circulation develops via:
- ✓ Azygos-hemiazygos system.
- ✓ Internal thoracic veins.
- ✓ Lateral thoracic veins.
- ✓ Vertebral plexus.



### Obstruction at different levels



Lesion location	Grade A Severity	Grade B severity	Grade C severity
Type I – Bilateral brachiocephalic vein occlusion with or without supra-azygos SVC	Moderate to severe (50-90%)	Pre-occlusive (>90%)	Totally occluded (100%)
Type II – Supra-Azygos SVC without brachiocephalic involvement	Moderate to severe (50-90%)	Pre-occlusive (>90%)	Totally occluded (100%)
Type III – Azygos SVC	Moderate to severe (50-90%)	Pre-occlusive (>90%)	Totally occluded (100%)
Type IV – Infra-Azygos SVC	Moderate to severe (50-90%)	Pre-occlusive (>90%)	Totally occluded (100%)

### **CLINICAL FEATURES:**

- Symptoms:
- ✓ Dyspnea (commonest symptom)
- ✓ Neck and upper limb swelling
- ✓ Facial swelling and plethora (worse on bending forward)
- ✓ Headache, dizziness, visual disturbances
- ✓ Cough, hoarseness, chest pain
- ✓ Dysphagia (if esophagus compressed)

#### Signs:

- ✓ Distended neck veins (non-pulsatile)
- √ Facial and upper limb edema
- ✓ Dilated superficial veins on chest wall
- √ Cyanosis
- √ Stridor (if larynx/trachea compressed)
- ✓ Papilledema (rare, suggests cerebral edema)

### **DIAGNOSIS:**

#### Clinical Diagnosis

✓ Based on typical signs and symptoms.

#### Imaging

#### 1. Chest X-ray

✓ Mediastinal widening, mass, pleural effusion

#### 2. Contrast-enhanced CT (CECT) of chest

- ✓ Identifies site, extent, and cause of obstruction
- √ Shows collateral venous circulation

#### **3. MRI**

✓ Alternative to CT for evaluating soft tissue

#### 4. Venography

- ✓ Gold standard investigation
- ✓ Now rarely needed

#### •5. PET-CT

✓ For staging of malignancies.

#### Tissue Diagnosis

- ✓ Biopsy of mass (e.g., bronchoscopy, mediastinoscopy, CT-guided FNAC).
- ✓ Pleural fluid cytology, if present.

### **GRADING OF SVC OBSTRUCTION**

✓ Grade I - Mild symptoms. Mild facial edema or plethora, no venous distention.

- ✓ **Grade II** Moderate symptoms. Facial and neck edema, jugular venous distension.
- ✓ Grade III Severe symptoms. Facial, neck, and upper limb edema, prominent chest wall collaterals.
- ✓ Grade IV Severe symptoms including cerebral edema, airway compromise, syncope, coma

### **MANAGEMENT:**

#### Supportive Measures :

√ Head elevation

✓ Oxygen

✓ Corticosteroids (e.g., dexamethasone) – useful in lymphoma

✓ Diuretics – to reduce edema

- Specific Treatment :
- Depends on the etiology
- **✓ Malignant SVCS:**
- ✓ Radiotherapy (NSCLC, lymphoma) rapid symptom relief

✓ Chemotherapy (esp. small-cell lung cancer or lymphoma)

✓ Endovascular stenting – rapid relief; bridge to definitive therapy.

✓ Anticoagulation – if thrombosis is present.

✓ **Thrombolysis** – selected cases with recent thrombus.

#### ✓ Benign SVCS:

✓ Anticoagulation

√ Stent placement

√ Surgical bypass (rare, last resort)

### PROGNOSIS:

Depends on underlying cause.

✓ Poor in malignant causes (e.g., lung cancer)

✓ Good in benign or treatable malignancies. (e.g., lymphoma)

✓ Stenting provides rapid and often dramatic symptomatic relief.

### **COMPLICATIONS:**

Cerebral edema

■Laryngeal/tracheal obstruction → respiratory failure

• Thromboembolism

### **DIFFERENTIAL DIAGNOSIS:**

Congestive heart failure

Angioedema

 Based on the histopathological report, the diagnosis is poorly differentiated squamous cell carcinoma of lung.

 Based on the radiological findings the TNM staging of the cancer is T4 N3 M1c.

## Stage Grouping of NSCLC (Including Squamous Cell Carcinoma)

Stage	TNM	
Stage 0	Tis N0 M0	
Stage IA <sub>1</sub>	T1b N0 M0	
Stage IA <sub>2</sub>	T1c N0 M0	
Stage IB	T2a N0 M0	
Stage IIB	T1-2 N1 M0	
Stage IIA	T1-2 N2 M0/T3 N0 M0 T4 N0-1 M0	
Stage IIIB	T3–4 N2 M0 / Any T N3 M0 T4 N0–1 M	
Stage IIIC	T4 N3 M0	
Stage IVA	Any T Any N M1a or M1b	
Stage IVB	Any T Any N M1c	

 Based on the stage grouping of squamous cell lung cancer, this is Stage IV B.

 Treatment varies by stage, performance status, and comorbidities.

The treatment for stage IV cancer is

✓ Goal: Palliative, prolong survival and improve QoL

✓ Chemotherapy: Platinum-doublet (cisplatin/carboplatin + gemcitabine or paclitaxel)

#### **✓Immunotherapy:**

- PD-L1 ≥1%: Pembrolizumab monotherapy or in combination
- PD-L1 <1%: Combination chemo-immunotherapy

✓ Targeted therapy: Rare in SCC due to low incidence of EGFR, ALK mutations

✓ Radiation: For symptom relief (e.g., bone pain, brain metastasis).

Thank you!